Date on Master's Thesis/Doctoral Dissertation
Pharmacology and Toxicology
Pharmacology and Toxicology, MS
Committee Co-Chair (if applicable)
Paraoxonase 2; PON2; cancer; non-small cell lung carcinoma; NSCLC
Non-small cell lung carcinoma (NSCLC) comprises 85% of lung cancer diagnoses and is plagued by drug resistance. Thus, elucidating the underlying mechanisms of NSCLC is paramount to expand future treatment options. Paraoxonase 2 (PON2), an intracellular enzyme with arylesterase and lactonase functions, has well-established anti-atherosclerotic activity. Recent studies show PON2 is overexpressed in a variety of tumors and confers drug resistance, although these interactions have not been thoroughly examined in NSCLC. Thus, we sought to investigate the role of PON2 in cellular proliferation using PON2-knockout mice, primary mouse cells, and NSCLC cell lines. Using these approaches, we demonstrate that PON2 is required for NSCLC proliferation, but dispensable for normal mouse development and non-transformed cell proliferation. These observations highlight PON2 as a potential therapeutic target against NSCLC.
Whitt, Aaron, "Paraoxonase 2 is critical for non-small cell lung carcinoma proliferation." (2019). Electronic Theses and Dissertations. Paper 3236.